CSF YKL-40, a glycoprotein and biomarker of glial inflammation, is associated with a cerebral structural signature distinct from that related to p-tau neurodegeneration at the earliest stages of cognitive decline due to AD (Gispert et al., 2016). Here, MAPT is linked to Alzheimer disease.